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Trypanosoma brucei gambiense was isolated twice from each of 23 patients in Côte d’Ivoire. Genetic 
characterization using RAPD (Random Primed Amplified Polymorphic DNA) showed additional 
variability within a given isoenzyme profile (zymodeme), confirming that this fingerprinting method has 
a higher discriminative power (faster molecular clock) than isoenzymes. RAPD confirmed also the 
evidence of multiple infections by different genotypes in the same patient despite a low genetic 
variability among Trypanosoma brucei gambiense stocks. The involvement of this phenomenon in 
treatment failure is discussed.  
 





Human African Trypanosomiasis (HAT) is a serious 
health problem in the sub-Saharan part of Africa. It is 
estimated that about 600 000 people are infected in 2003 
(W.H.O., personal communication). In West Africa, the 
causative agent of the chronic form of the disease is 
Trypanosoma brucei gambiense. However, diversified 
clinical evolutions were recorded in Côte d’Ivoire 
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2000 a, Truc et al., 1997). The taxonomic status of the 
subspecies described within the complex T. brucei is still 
under debate, mainly because geographical distribution 
and pathogenicity of the subspecies are difficult to link 
with clear genetic categories (Jamonneau et al., 2002). 
Indeed, the only clear-cut genetic subdivision remains T. 
brucei gambiense group 1 (Gibson, 1986), while it is 
unclear whether T. b. brucei and T. b. rhodesiense 
correspond to distinct phylogenetic subdivisions 
(Mathieu-Daudé et al., 1994). Trypanosomes were 
genetically characterized using different methods, 
including Multilocus Enzyme Electrophoresis (MLEE) and 
several molecular methods (Gibson et al., 1999), such as  
 




Table 1. Patient code number, stocks isolated twice from each patient (A and B), corresponding location and focus and 
year of isolation in Côte d’Ivoire. 
 
Patient/DNA Location Focus Year 
611 A and B Yaokro Sinfra 1997 
622 A and B Yaokro Sinfra 1997 
2499 A and B Sinfra Sinfra 1996 
2562 A and B Dioulabougou Sinfra 1997 
5/7A and B Sinfra Sinfra 1999 
93/5 A and B Sinfra Sinfra 1997 
634 A and B Konéfla Sinfra 1997 
614 A and B Yaokro Sinfra 1997 
659 A and B Bonon Bonon 1998 
51/11 A and B Sinfra Sinfra 1997 
664 A and B Bonon Bonon 1998 
666 A and B Bonon Bonon 1998 
4/ 5 A and B Sinfra Sinfra 1999 
687 A and B Bouaflé Bonon 1998 
806/9 A and B Aboisso Aboisso 1997 
B120/9 A and B Aboisso Aboisso 1997 
654 A and B Bouaflé Bonon 1998 
662 A and B Bonon Bonon 1998 
668 A and B Bonon Bonon 1998 
669 A and B Bonon Bonon 1998 
694 A and B Bouaflé Bonon 1998 
2508 A and B Bonon Bonon 1997 




Random Primed Amplified Polymorphic DNA (RAPD) 
(Tibayrenc et al., 1993), ribosomal gene 18S sequencing 
(Stevens, 1999) or microsatellites (Biteau et al., 2000, 
Truc et al., 2002). 
This study has been conducted in Côte d’Ivoire where 
parasites were isolated twice from each patient at 
different time, first during the medical survey in the field, 
and second when arriving at the hospital before 
treatment (Truc et al., 2002). Isolates were cultivated in 
vitro, then genetically characterised by RAPD. The aim of 
this study was first, to record the diversity of T. brucei 
genotypes circulating in this area, and then, to confirm 
the evidence of multiple infections as previously 








Twenty three patients were diagnosed according to standard 
procedures (WHO, 1998) between 1996 and 1999 by the Ivoirian 
National Control Program in three foci of Côte d’Ivoire: Sinfra and 
Bonon in central-western part and Aboisso in the eastern part of the 
country, on the border with Ghana (Table 1). Consenting patients 





Trypanosomes were isolated using the Kit for In Vitro Isolation of 
trypanosomes (KIVI, Aerts et al., 1992). Reference stocks were 
included: JUA and PEYA (T. b. gambiense group 1), TSW65 and 
KP465 (T. brucei “ bouaflé ” group), 058Cl.A3 (T. b. rhodesiense), 
EATRO 1125 (T. b. brucei) and TRPZ105 (T. congolense, 
savannah group). These reference stocks were previously studied 
by Truc et al. (1993, 1997) and Mathieu-Daudé et al. (1994). 
Isolates and reference stocks were cultivated in semi-defined 
medium (Cunningham, 1977). Parasite pellets were collected, 
prepared and stored at -20°C according to Truc et al. (1991, 1993, 
2002). For each patient, two pellets labelled A and B corresponded 
respectively to the cultures initiated from each of the two isolates 
(Truc et al., 2002).  
 
 
RAPD (Random Primed Amplified Polymorphic DNA)  
 
DNAs were extracted according to the method described by Oury et 
al. (1997). RAPD amplifications were performed according to the 
protocol described by Welsh and McClelland (1990) and Williams et 
al. (1990) and modified by Tibayrenc et al. (1993). Genomic DNA 
samples (20 ng) were amplified in 60 µl  of  specific  buffer  (10  mM 
 




Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, pH 8.3), supplied by Roche 
Diagnostics (Mannheim, Germany), in presence of 0.2 µM of 
primer, 4 x 100 µM dNTP and 0.9 U of Taq DNA Polymerase 
(Roche Diagnostics, Mannheim, Germany). The characterization 
was based on the use of ten base-long primers from Operon 
Technologies (USA). One hundred and twenty primers were first 
screened on the set of the seven reference stocks. Twenty primers 
were selected on the basis of two criteria, namely the readability 
and the reproducibility of the patterns obtained: A2, A4, A8, A10, 
A11, A15, A16, A18, A19, A20, B1, B8, B9, B18, F3, F4, F10, N20, 
U3 and U18 (see primer sequences through Operon Technologies, 
USA). The amplification program was performed on a PTC 100-60 
thermocycler (MJ Research Inc., Watertown, Massachusetts, USA) 
and consisted of 45 cycles at 94°C for 1 min, 36°C for 1 min and 
72°C for 2 min and a final elongation step at 72°C for 7 min. 
Amplified DNA was kept at +4°C until analysis. Amplifications were 
repeated three times for each primer. 
Amplification products were separated by electrophoresis on 
1.6% agarose gels with TAE buffer (40 mM Tris-acetate pH 7.5, 1 






The Jaccard distance was calculated to estimate the genetic 
differences among the stocks (Jaccard, 1908). DNA bands were 
coded starting from the slowest band. All genotypes were computed 
thanks to the Genetics software designed and optimized in our 
laboratory by S. Noël and performed using Sun stations. The 
UPGMA (Unweighted pair-group method with arithmetic average) 
dendogram was built from the Jaccard distance matrix according to 
Sneath and Sokal (1973). 
 
 
RESULTS AND DISCUSSION 
 
46 stocks were isolated from 23 patients (i.e. 2 stocks 
from each patient). Amplification patterns showed a 
maximum of seven bands for a given primer. Because of 
the high number of primers used for 46 stocks, observed 
bands are not detailed in a table. All 46 newly isolated 
stocks fell into only one cluster, which was genetically 
fairly homogeneous (Figure 1). When compared with JUA 
and PEYA reference stocks, results confirmed that the 46 
stocks under study belong to the T. b. gambiense group 1 
identified as zymodeme 3 (Z3, Jamonneau et al, 2000 b). 
Out of 23 pairs of stocks, only 13 pairs were strictly 
identical and showed no detectable genetic difference. 
The remaining ten pairs showed slight genetic 
differences (d<0.1). Out of twenty primers, sixteen 
showed no variability for all 46 stocks. Using the four 
remaining primers (A2, B18, F10 and N20), most part of 
the bands was shared by all 46 stocks: the differences 
observed between patterns involved only one band.  
The additional genetic variability evidenced in the 
present study by RAPD analysis within a given 
zymodeme (Z3) confirms that RAPD has a higher 
discriminatory power than MLEE, at least in the case of 
T. brucei spp.. This is due to the fact that the various 
genomic regions randomly surveyed by RAPD have an 





limited genetic variability corroborates the pattern 
previously found in T. b. gambiense group 1 (see Gibson 
et al., 1999). A similar result was observed for some 
lower genetic subdivisions of T. cruzi (Tarrieu, 1993, 
Tibayrenc et al., 1993, Barnabé et al., 2000). For a given 
primer, a difference of only one band when comparing 
two stocks isolated from the same patient could be 
considered either as an artefact, a mutation or a limited 
genomic rearrangement. However the occurrence of 
artefact bands in our results is improbable because the 
reproducibility of all patterns has been checked for. Thus 
it can be considered that these different patterns 
correspond to different, although closely related 
genotypes. 
While ten pairs of stocks were different when using 
RAPD analysis, only two were detected using TBDAC 1/2 
and TRBPA 1/2 microsatellite markers (Truc et al., 2002). 
Only the 614A and B pair of stocks were different by 
using both microsatellite and RAPD typing methods. The 
634A and B pair of stocks were different for TBDAC 1/2, 
but not for RAPD. 
The present results suggest the occurrence of mixtures 
of T. brucei genotypes within a given HAT patient. 
However, (i) it is interesting to note that all double 
infections involve very closely related genotypes. A totally 
different result was observed in T. cruzi, since mixed 
infections with drastically divergent clonal genotypes are 
commonplace in a given chagasic patient (Tibayrenc et 
al., 1986); (ii) one cannot rule out the hypothesis that 
such slight differences are explainable, not by original 
infection by two different genotypes, but rather, by point 
mutation or limited genomic rearrangement occurring 
after infection by only one genotype. Mixtures of 
genotypes in HAT patients were already suspected 
through the double isolation of stocks from the same 
patient, the in vitro isolation of stocks using KIVI, the 
proportion of stumpy and slender forms at the time of 
blood inoculation into KIVI (Truc et al., 2002).  
The existence of mixtures of genotypes might play a 
role on HAT pathogenicity, and on several researches 
such as treatment failure, since different T. brucei 
genotypes may have different virulence and different drug 
sensitivities. It is probable that the frequency of mixtures 
of genotypes has been until now underestimated, since 
the process of isolation and culturing introduces a 
selection, which could eliminate one genotype and not 
the other. Evaluation of drug sensitivity of a stock isolated 
from a given patient might therefore be not reliable. 
Further investigations are required to determine 
accurately the potential impact of mixtures of T. brucei 
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Figure 1. UPGMA dendrogram built using Jaccard distances for each pair of stocks (A and B) isolated from the same patient (code number). 
For reference stocks JUA and PEYA (T. b .gambiense group 1), TSW65 and KP465 (T. brucei “ bouaflé ” group), 058Cl.A3 (T. b. 
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